SI1499360T1 - Formulacija, ki obsega buprenorfin - Google Patents
Formulacija, ki obsega buprenorfinInfo
- Publication number
- SI1499360T1 SI1499360T1 SI200331468T SI200331468T SI1499360T1 SI 1499360 T1 SI1499360 T1 SI 1499360T1 SI 200331468 T SI200331468 T SI 200331468T SI 200331468 T SI200331468 T SI 200331468T SI 1499360 T1 SI1499360 T1 SI 1499360T1
- Authority
- SI
- Slovenia
- Prior art keywords
- buprenorphine
- chitosan
- ester
- delivered
- formulation
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 5
- 229960001736 buprenorphine Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001661 Chitosan Polymers 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000032050 esterification Effects 0.000 abstract 1
- 238000005886 esterification reaction Methods 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000001814 pectin Substances 0.000 abstract 1
- 235000010987 pectin Nutrition 0.000 abstract 1
- 229920001277 pectin Polymers 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0206448A GB0206448D0 (en) | 2002-03-19 | 2002-03-19 | Analgesics |
| GB0225042A GB0225042D0 (en) | 2002-10-28 | 2002-10-28 | Pharmaceutical composition |
| GB0225040A GB0225040D0 (en) | 2002-10-28 | 2002-10-28 | Formulation |
| GB0225041A GB0225041D0 (en) | 2002-10-28 | 2002-10-28 | Pharmaceutical formulation |
| EP03712380A EP1499360B1 (en) | 2002-03-19 | 2003-03-19 | Formulation comprising buprenorphine |
| PCT/GB2003/001183 WO2003080021A2 (en) | 2002-03-19 | 2003-03-19 | Formulation comprising buprenorphine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1499360T1 true SI1499360T1 (sl) | 2009-04-30 |
Family
ID=28457822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200331468T SI1499360T1 (sl) | 2002-03-19 | 2003-03-19 | Formulacija, ki obsega buprenorfin |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US7666876B2 (sl) |
| EP (3) | EP1499360B1 (sl) |
| JP (3) | JP4728580B2 (sl) |
| KR (2) | KR20110005919A (sl) |
| CN (1) | CN1642577B (sl) |
| AT (2) | ATE422902T1 (sl) |
| AU (2) | AU2003216842B2 (sl) |
| BR (1) | BRPI0308527B1 (sl) |
| CA (2) | CA2479718A1 (sl) |
| DE (2) | DE60323958D1 (sl) |
| DK (2) | DK1499360T3 (sl) |
| ES (2) | ES2325364T3 (sl) |
| GB (1) | GB2397016B (sl) |
| IL (2) | IL164129A0 (sl) |
| MX (1) | MXPA04009055A (sl) |
| NZ (2) | NZ535973A (sl) |
| PT (1) | PT1513493E (sl) |
| SI (1) | SI1499360T1 (sl) |
| WO (2) | WO2003080021A2 (sl) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) * | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| GB0328186D0 (en) * | 2003-12-05 | 2004-01-07 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| US20050129679A1 (en) | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| US8202550B2 (en) * | 2004-10-11 | 2012-06-19 | Nasaleze Ppm Limited | Compositions for intranasal administration |
| AU2005313365A1 (en) * | 2004-12-06 | 2006-06-15 | Janssen Pharmaceutica N.V. | Oral suspension comprising meloxicam |
| EP2179741B1 (en) * | 2005-08-26 | 2014-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administraton of oxytocin |
| GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| AU2007236003B2 (en) * | 2006-04-04 | 2012-10-18 | Emodys Gmbh | Use of kappa opioid receptor antagonist-containing compositions for the treatment of dissociative disorders |
| KR101329496B1 (ko) * | 2006-07-21 | 2013-11-13 | 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 | 향상된 흡수를 갖는 경점막 전달 장치 |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| KR20090125748A (ko) * | 2007-04-02 | 2009-12-07 | 토요 보세키 가부시기가이샤 | 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법 |
| EP2057982A1 (en) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| JP2011511674A (ja) | 2008-02-07 | 2011-04-14 | ユニヴァーシティ オブ ワシントン | 周方向エアロゾルデバイス |
| CN101297973B (zh) * | 2008-05-22 | 2010-06-09 | 武汉华纳生物工程有限公司 | 高生物粘附温敏水凝胶及其制备方法和用途 |
| WO2010072398A2 (en) * | 2008-12-22 | 2010-07-01 | Boehringer Ingelheim Limited | Veterinary formulations |
| DE102009001041A1 (de) * | 2009-02-20 | 2010-08-26 | Marien-Apotheke Fulda Ohg | Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot |
| DE102009024542A1 (de) | 2009-06-10 | 2010-12-16 | Arivine Pharma Ag | Zusammensetzungen auf Basis von Chitosan-Oligosacchariden |
| CN102686221B (zh) * | 2009-07-27 | 2018-04-17 | 诺西赛普塔有限责任公司 | 治疗疼痛的方法 |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| CZ302789B6 (cs) | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
| WO2012077024A1 (en) * | 2010-12-08 | 2012-06-14 | Mrinmayee Kondhalkar | Composition for inhibiting the growth of mammalian hair |
| RU2612506C2 (ru) | 2011-03-03 | 2017-03-09 | Импел Ньюрофарма Инк. | Устройство для назальной доставки лекарственных средств |
| AU2012253569B2 (en) | 2011-05-09 | 2018-02-15 | Impel Pharmaceuticals Inc. | Nozzles for nasal drug delivery |
| BR112013029126A2 (pt) * | 2011-05-13 | 2017-02-07 | Euro Celtique Sa | formas de dosagem farmacêuticas intranasais compreendendo naloxona |
| WO2013011477A1 (en) * | 2011-07-20 | 2013-01-24 | Torrent Pharmaceuticals Ltd | Pharmaceutical invention of tapentadol |
| AU2012296346A1 (en) | 2011-08-18 | 2014-04-03 | Biodelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| WO2013040295A2 (en) * | 2011-09-14 | 2013-03-21 | University Of South Florida | Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| CA2909954C (en) | 2013-04-28 | 2021-03-23 | Impel Neuropharma, Inc. | Medical unit dose container |
| US9918981B2 (en) | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| US9867818B2 (en) | 2013-09-10 | 2018-01-16 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| US9839611B2 (en) | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| EP3043777B1 (en) | 2013-09-10 | 2020-04-22 | Fresh Cut Development, LLC | Sublingual buprenorphine spray |
| WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| WO2015155544A1 (en) * | 2014-04-10 | 2015-10-15 | Patrick Crowley | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
| US20150359738A1 (en) * | 2014-06-16 | 2015-12-17 | Loewi LLC | Methods of Anesthetizing Nerve Tissue in the Trigeminal Nerve Pathway and Medical Uses Thereof |
| ES2963707T3 (es) | 2015-01-07 | 2024-04-01 | Tonix Pharma Ltd | Formulaciones de oxitocina que contienen magnesio y métodos de uso |
| BR112018000200A2 (pt) * | 2015-07-10 | 2018-09-04 | Dsm Ip Assets B.V. | composições de comida e/ou ração para prevenir e tratar doenças inflamatórias |
| NZ741171A (en) | 2015-09-10 | 2022-01-28 | Impel Neuropharma Inc | In-line nasal delivery device |
| TN2019000117A1 (en) * | 2016-10-28 | 2020-10-05 | Servier Lab | Liposomal formulation for use in the treatment of cancer |
| KR102660711B1 (ko) * | 2017-10-20 | 2024-04-26 | 키에시 파르마슈티시 엣스. 피. 에이. | 활성 성분으로서 오피오이드 수용체 효능제를 포함하는 약제학적 제제, 그의 제조 방법 및 치료적 사용 |
| EP3713626A4 (en) | 2017-11-21 | 2021-08-18 | Impel Neuropharma Inc. | INTRA-NASAL DEVICE WITH INPUT INTERFACE |
| WO2019104205A1 (en) | 2017-11-21 | 2019-05-31 | Impel Neuropharma, Inc. | Intranasal device with dip tube |
| WO2019136308A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| EP4147699A1 (en) | 2018-01-05 | 2023-03-15 | Impel Pharmaceuticals Inc. | Intranasal delivery of dihydroergotamine by precision olfactory device |
| CN112955134A (zh) | 2018-07-19 | 2021-06-11 | 英倍尔药业股份有限公司 | 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送 |
| BR112021013244A8 (pt) | 2019-01-03 | 2022-10-18 | Impel Neuropharma Inc | Dispositivo de entrega de fármaco nasal |
| IT201900006104A1 (it) * | 2019-04-18 | 2020-10-18 | S I I T S R L Servizio Int Imballaggi Termosaldanti | Metodo di preparazione di un prodotto a base di chitosano |
| KR20220010011A (ko) | 2019-05-17 | 2022-01-25 | 임펠 뉴로파마 인코포레이티드 | 일회용 비강 전달 장치 |
| WO2021225973A1 (en) * | 2020-05-04 | 2021-11-11 | Amphastar Pharmaceuticals, Inc. | Naloxone pharmaceutical formulations for intranasal (in) delivery |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2125212A (en) * | 1938-05-03 | 1938-07-26 | Vick Chemical Company | Therapeutic composition |
| US2730483A (en) * | 1952-08-12 | 1956-01-10 | Nepera Chemical Co Inc | Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine |
| BE623427A (sl) * | 1961-10-10 | |||
| JPS5885813A (ja) * | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| US4486423A (en) * | 1983-04-21 | 1984-12-04 | Janssen Pharmaceutica Inc. | Stable fentanyl composition |
| US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| HU193780B (en) * | 1985-06-21 | 1987-11-30 | Richter Gedeon Vegyeszet | Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof |
| FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JPS62123112A (ja) * | 1985-11-22 | 1987-06-04 | Sunstar Inc | 軟膏基剤 |
| DE3601132A1 (de) * | 1986-01-16 | 1987-07-23 | Christian Bannert | Verfahren zur behandlung der schleimhaut |
| US4826683A (en) * | 1987-01-09 | 1989-05-02 | Bates Harry L | Decongestant |
| US5200180A (en) * | 1987-06-26 | 1993-04-06 | Christian Bannert | Pharmaceutical composition for the treatment of the human eye |
| DE3726797A1 (de) * | 1987-08-12 | 1989-02-23 | Bayer Ag | Arzneimittel fuer den bereich der mundhoehle |
| US4915948A (en) * | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
| US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| DE3827561C1 (sl) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| GB8904370D0 (en) | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
| JP2911496B2 (ja) * | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| DE69222295T2 (de) | 1992-05-26 | 1998-04-09 | Procter & Gamble | Pulverförmige pharmazeutische Zusammensetzung |
| WO1994010987A1 (en) | 1992-11-09 | 1994-05-26 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
| ATE241984T1 (de) * | 1993-03-26 | 2003-06-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| GB9406171D0 (en) * | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| CA2186750C (en) * | 1994-03-30 | 2008-08-05 | Jens Hansen | Use of fatty acid esters as bioadhesive substances |
| AU700162B2 (en) * | 1994-05-13 | 1998-12-24 | Aradigm Corporation | Narcotic containing aerosol formulation |
| FR2733420B1 (fr) | 1995-04-28 | 1997-06-27 | Sep Tarral | Preparations pectiques utilisables comme support de medicament |
| DE19527411A1 (de) * | 1995-07-27 | 1997-01-30 | Ackermann & Schmitt Gmbh & Co | Kupplung |
| US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
| US6667279B1 (en) * | 1996-11-13 | 2003-12-23 | Wallace, Inc. | Method and composition for forming water impermeable barrier |
| US5725263A (en) * | 1997-04-03 | 1998-03-10 | Rodriguez; Ernest L. | Door securing device |
| GB9707934D0 (en) * | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
| RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| EP1035833B1 (en) | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Compositions for nasal administration |
| US6090368A (en) * | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| CA2341732C (en) | 1998-08-26 | 2008-08-19 | Teijin Limited | Powder composition for nasal administration |
| JP2000229859A (ja) | 1999-02-12 | 2000-08-22 | Teijin Ltd | 安定なブプレノルフィン経鼻製剤 |
| US6541021B1 (en) * | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
| JP2001002589A (ja) | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
| WO2001015735A1 (fr) * | 1999-08-26 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Matrice adherant a la muqueuse nasale |
| GB9924797D0 (en) | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| WO2002011778A1 (en) * | 2000-05-10 | 2002-02-14 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
| US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| GB2378383A (en) | 2001-06-06 | 2003-02-12 | Gursharan Moonga | Nasal delivery of pharmaceutical compositions in powder form |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) * | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
-
2002
- 2002-03-19 US US10/508,336 patent/US7666876B2/en not_active Expired - Fee Related
-
2003
- 2003-03-19 CA CA002479718A patent/CA2479718A1/en not_active Abandoned
- 2003-03-19 JP JP2003577851A patent/JP4728580B2/ja not_active Expired - Fee Related
- 2003-03-19 KR KR1020117000035A patent/KR20110005919A/ko not_active Application Discontinuation
- 2003-03-19 CA CA2479711A patent/CA2479711C/en not_active Expired - Fee Related
- 2003-03-19 MX MXPA04009055A patent/MXPA04009055A/es active IP Right Grant
- 2003-03-19 AU AU2003216842A patent/AU2003216842B2/en not_active Ceased
- 2003-03-19 ES ES03715087T patent/ES2325364T3/es not_active Expired - Lifetime
- 2003-03-19 KR KR1020047014665A patent/KR101030403B1/ko not_active IP Right Cessation
- 2003-03-19 PT PT03715087T patent/PT1513493E/pt unknown
- 2003-03-19 NZ NZ535973A patent/NZ535973A/en unknown
- 2003-03-19 ES ES03712380T patent/ES2315485T3/es not_active Expired - Lifetime
- 2003-03-19 DK DK03712380T patent/DK1499360T3/da active
- 2003-03-19 DK DK03715087T patent/DK1513493T3/da active
- 2003-03-19 CN CN038063646A patent/CN1642577B/zh not_active Expired - Fee Related
- 2003-03-19 AU AU2003219282A patent/AU2003219282A1/en not_active Abandoned
- 2003-03-19 GB GB0318346A patent/GB2397016B/en not_active Expired - Fee Related
- 2003-03-19 NZ NZ535972A patent/NZ535972A/en not_active IP Right Cessation
- 2003-03-19 WO PCT/GB2003/001183 patent/WO2003080021A2/en active Application Filing
- 2003-03-19 EP EP03712380A patent/EP1499360B1/en not_active Expired - Lifetime
- 2003-03-19 EP EP03715087A patent/EP1513493B8/en not_active Expired - Lifetime
- 2003-03-19 SI SI200331468T patent/SI1499360T1/sl unknown
- 2003-03-19 AT AT03715087T patent/ATE422902T1/de active
- 2003-03-19 JP JP2003577852A patent/JP2005527535A/ja not_active Withdrawn
- 2003-03-19 BR BRPI0308527-9A patent/BRPI0308527B1/pt not_active IP Right Cessation
- 2003-03-19 IL IL16412903A patent/IL164129A0/xx unknown
- 2003-03-19 AT AT03712380T patent/ATE410187T1/de active
- 2003-03-19 DE DE60323958T patent/DE60323958D1/de not_active Expired - Lifetime
- 2003-03-19 US US10/508,315 patent/US20050142072A1/en not_active Abandoned
- 2003-03-19 DE DE60326231T patent/DE60326231D1/de not_active Expired - Lifetime
- 2003-03-19 WO PCT/GB2003/001184 patent/WO2003080022A2/en active Application Filing
- 2003-03-19 EP EP07020868A patent/EP1878446A3/en not_active Withdrawn
-
2004
- 2004-09-19 IL IL164129A patent/IL164129A/en not_active IP Right Cessation
-
2007
- 2007-05-14 US US11/798,384 patent/US20070231269A1/en not_active Abandoned
-
2009
- 2009-10-19 US US12/588,528 patent/US20100041624A1/en not_active Abandoned
-
2010
- 2010-03-26 JP JP2010071698A patent/JP2010174029A/ja active Pending
-
2011
- 2011-01-12 US US12/929,279 patent/US20110105551A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1499360T1 (sl) | Formulacija, ki obsega buprenorfin | |
| HK1088547A1 (en) | Once daily dosage forms of trospium trospium | |
| HUP0400607A2 (hu) | Orális szabályozott hatóanyag-leadású készítmény szív- és keringési betegségek napi egyszeri gyógyszerezéssel való kezelésére és megelőzésére | |
| IL209703A0 (en) | Controlled release hydrocodone formulations | |
| IL169480A (en) | Pharmaceuticals containing fentanyl for intravenous administration | |
| CA2478980A1 (en) | Pulmonary delivery for levodopa | |
| ZA200600027B (en) | Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| WO1999004772A3 (en) | Use of levobupivacaine | |
| EP1393734A4 (en) | DRUG AGAINST DARMER DISEASES | |
| HK1045464A1 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease | |
| WO2005044187A3 (en) | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same | |
| WO2002102743A3 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
| CA2180178A1 (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| WO2022026622A3 (en) | Treatment of viral diseases | |
| MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
| WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
| WO2002072016A3 (en) | Method of preventing adhesions with ifn-¿y? | |
| WO2003072021A3 (en) | Oral pediatric trimethobenzamide formulations and methods | |
| EP1413302A3 (en) | Substituted guanidines for the treatment of pain |